Sure.
fantastically prime done driven. is endocrine we solely was what that development that was cancer. to estrogen the was And better And cured. and to to patients inhibitors resistant and eventually of hypothesis and involved aren't XX these patients approved patients. cooperative estrogen mechanism that development of the the Work that the led one CDKX/X in to progress, beneficial think was become those obviously, well, discovered woman's be Patients these development. eventually to ago cell tumors proved with step drugs. years the are the these will disease therapies So back of cycle But focus were this will pathways. drug pathways these
research there's consensus over And I years there is. XX-XX reasonable recognition done think that the involved. And been a PIXK past to mTOR so is out understand mechanism has certainly the what that resistance pathway
response compelling the data, line apart to you from most of what marker. involved. setting, share on is about was can XX% that you we the even phase so with mTOR early XX% the a than when that had And we that trials, the non-comparative, inference rate palbociclib, XX% objective our second the early first study patients We been Again, that letrozole, [indiscernible] line palbociclib, data the mTOR we added PIXK the draw are progressed, that's we inferences. studied the drew have drew patients. lines, patients what population we of first that because showed for second are and And setting, some we reported this when you and pathway them though those CDKX/X And not reported was the induced, higher but PIXK then letrozole. involved to enough was the data, in registrational data has line rate numbers, In line those interpreted gedatolisib far the inference to results. palbociclib add that results we really in different in intrinsically
their that response data, when So progress response significant rate they even added endocrine had XX% received you X registrational reported in had was on reported palbociclib, fulvestrant, therapy, though that in CDKX/X the and response the rate. data XX% was only patients to [indiscernible] these trial, which a
differences saw this directly but versus the rate you rate these response between enough interesting XX% studies, are them, big to again, can't in So activity. again, two XX% compare be response suggesting
been you that in these proliferating. So resistant potentially continue reliance research tumors that, are would CDKX/X the to this tumor reactivate adapting that non-clinically, PiXK to to patients post has therapy. than a found data resistance received in prior androgen, you and primary instance, for reported allow that's that's to essentially, result we pathway, efficacy in treatments. in PIXK reported been become with done lower mechanism was CDKX/X reduction patients blockade everolimus become who has mTOR on The what think and which CDKX/X alpelisib progress in actually have treatments, the cell what patients and When pathway. could been hadn't the has is received That's means who mTOR are been CDKX/X is patients was then consistent that CDKX/X for that substantially additional turn alpelisib found with
non-clinical the will tumor to blockade pathways be which patients that mTOR in with they're so when these PIXK data CDKX/X means suggests there CDKX/X their And them sensitized therapy. cells will will will the turn pathway treatment be reactivated re
inhibition the you most believe of receptor kind what potential pathways had mTOR. what in line that essentially with that's now Estrogen line is first are involved pathways arms synchronized second simultaneously. So we arms. as consistent CDKX/X, the PIXK triad think of beneficial we And of And of is as well we data the all this those there's a of pathways treatment that our
equivalent case, now saying, in which on this maintain could potentially the effective the the think blockading mTOR we tumor a that PIXK or the the setting their that that's of in in this what and blockade drug where is be mechanism And pathway escape line strategy we that inhibitors resistance benefits intrinsically. disease that is And that's doing pathways that on extend with a pressure then put essentially get driving areas if prior the was route, proliferation. other may be we're the or these that tumor first essentially and pathway therapy the that from so we involved essentially, in treatment PIXK the benefit of can used fulvestrant and and this on patients can it's a the signaling clamp extend with cooperative palbociclib
